Creapharm Establishes U.S. Subsidiary

Creapharm Europe has established a U.S. subsidiary, Creapharm-MP5, Inc. Through its subsidiaries Creapharm and MP5, Creapharm Europe manufacturers cytotoxic and other high-potency drugs as well as clinical supply services.

As part of the launch, Matthew Maupin has been appointed vice president of business development, North America. Mr. Maupin’s efforts will focus on promoting MP5’s services in the U.S. and Canada with particular focus on the oncology market. He will also promote Creapharm’s clinical supply offerings.

Most recently, Mr. Maupin was the vice president of business development for a U.S. CMO. Previously held leadership positions in quality and operations in addition to owning a research reagent business focused on RNAi (RNA interference).